All News
Vaccine Efficacy in Patients with Seronegative Spondyloarthritis
Vaccine efficacy remains an important and highly discussed topic at this year’s annual meeting given the ongoing COVID-19 global health crisis, current influenza season, and recently published 2022 ACR guidelines for vaccinations in patients with rheumatic and musculoskeletal diseases.
Read Article
McCormick et al Fruit juice and other sugar-sweetened drinks increase gout flare in dose-dependent manner @RheumNow #ACR22 Abstr#1805 https://t.co/aGg5i5XyTK https://t.co/x8ChwASM6P
Richard Conway RichardPAConway ( View Tweet)
A Novel Treatment Response Measurement Tool for Lupus
Dr. Dao discusses abstract 2054 with Dr. Morand at the #ACR22 Convergence. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process.
https://t.co/iqqyI953Vz https://t.co/taUjTHsrJ2
Links:
Dr. John Cush RheumNow ( View Tweet)
Even young SLE patients are still at high risk of severe COVID:
- in general pop, age is key factor
- in SLE, risk is high across age groups (maybe due to both meds & disease)
- vaccination makes a big diff but SLE pts still at high risk
ABST1591 @CCalabreseDO #ACR22 @RheumNow https://t.co/ra1F79ITn3
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #ACR22 annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
#ACR22 Abstr#1830 Short attack of arthritis episode is common in Familial Mediterranean Fever. Other pointers? A cohort study in Turkey showed to consider FMF in pts with red mono-oligo arthritis in lower limbs & spondyloarthropathy. 20% were colchicine resistant @RheumNow https://t.co/JXGcgCrhPu
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#1839 "Doctor, I have fever & recurrent right-sided tummy pain, is it my appendix?" A case-control study in Turkey reported 16% of unindicated appendectomies prior to FMF diagnosis. This group had late diagnosis and associated with M694V homozygous mutation @RheumNow https://t.co/QtxjuHDXYC
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
FitzGerald et al. PsA patients with higher levels of IL-23-IL-17 pathway biomarkers more likely to benefit from TYK2i deucravacitinib @RheumNow #ACR22 Abstr#2133 https://t.co/eVq4XQgX5l https://t.co/HZlTS5OZ2s
Richard Conway RichardPAConway ( View Tweet)
Mihai et al. Immunosuppressive treatment in SSc assoc lower GI symptom score. @RheumNow #ACR22 Abstr#2174 https://t.co/Y1gyRe8ron https://t.co/tz9cIESzqo
Richard Conway RichardPAConway ( View Tweet)
Wipfler et al. 1 in 17 individuals prescibed MTX experienced an unexpected barrier in Post-Roe era. @RheumNow #ACR22 Abstr#L09 https://t.co/a8RDZF3JKy https://t.co/cyxJj2adgw
Richard Conway RichardPAConway ( View Tweet)
Maughan et al inc the late, great, Justin Mason. Treatment cessation in TAK. Feasible in some patients. Initial treatment response, age and Numanotype V arterial involvement predictors. @RheumNow #ACR22 Abstr#L017 https://t.co/5t00prCtFT https://t.co/GGUUNQqyoL
Richard Conway RichardPAConway ( View Tweet)
Terrier @TerrierBen et al. PNEUMOVAS -pneumococcal vaccination in AAV treated with RTX Double dose of PCV13 at day 0 and day 7 followed by single dose of PPV23 at month 5 significantly improves antibody responses (2 in figure) @RheumNow #ACR22 Abstr#L016 https://t.co/qKqgvv7ZwI https://t.co/UHCuZNSF54
Richard Conway RichardPAConway ( View Tweet)
I see that despite the condensing of the #ACR22 to 3 days, people are keeping the tradition of leaving at the start of the last day despite it now being a full day. Personally don't think the 3 day meeting has worked, its too packed. @RheumNow
Richard Conway RichardPAConway ( View Tweet)
Promises to be a fantastic session!
🌟Delighted PMR is getting the attention it deserves 🌟
2pm GMT/ 9am EST
#ACR22 @RheumNow
@SattuiSEMD @EBRheum @drceowen https://t.co/ShRTS1DLXO
Patricia Harkins DrTrishHarkins ( View Tweet)
Wu et al Phase 3 RCT of Telitacicept (targets BlyS and APRIL) in SLE. Primary endpoint met at week 52! SRI(4) 67% vs 33% or 83% vs 38% (P<0.001 for both) depending on how you want to slice it. @RheumNow #ACR22 Abstr#L07 https://t.co/nnKr4AU8Jk https://t.co/9BVF6OljFQ
Richard Conway RichardPAConway ( View Tweet)
Fleischmann et al. Safety of TYK2i Deucravacitinib in PsA/PsO in terms of labs. Really no effect on lab values other than increase in trigs. Guess this is why they don't have lab monitoring on label? @RheumNow #ACR22 Abstr#2132 https://t.co/ueIVKQc6jr https://t.co/u99QE71VQ5
Richard Conway RichardPAConway ( View Tweet)
"Less steroid is more" in multiple diseases. Dr. J Kolfenbach #ACR22 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
van Nieuwland et al. Comparison US/PET/MRI in GCA. Good specificity but relatively low sensitivity for all. PET best for extra-cranial. MRI/US best for isolated cranial. @RheumNow #ACR22 Abstr#1617 https://t.co/CI3TtxOQJL https://t.co/3pJeGo49Gj
Richard Conway RichardPAConway ( View Tweet)
Stamatis et al. MI in systemic vasculitis vs controls. Only difference - less likely to have pre-existing CVD. No significant difference in outcomes - but this may be due to underpowered - see Figures. @RheumNow #ACR22 Abstr#1615 https://t.co/bYtMr1jGXN https://t.co/QABW2GiVFl
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Abstr#1756 More data on safety of #COVID vaccine to cite when counselling patients with inflammatory arthritis (IA). Data from COVAX registry (over 7000 pts) showed rates of serious adverse event was low 0.3% vs 2.5% in those with non-IA RMD group
@RheumNow https://t.co/iucDK1GpU4
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)